POLY MEDICURE
|
|
BOM : 531768     NSE : POLYMED     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Nov 12,2024 |
Price(EOD): ₹ 2,707.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Medical Equipment/Supplies/Accessories |
MCap: ₹ 27,431.53 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
POLY MEDICURE | -4.6% | 13.5% | 86.3% |
PREVEST DENPRO | -4% | -5.1% | 35.1% |
NURECA | -7.4% | -12.5% | -19.6% |
FUNDAMENTAL ANALYSIS OF POLY MEDICURE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF POLY MEDICURE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
93.73
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 292.74 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 18.71
P/B Calculated based on Book Value of Rs 1,466.65 Cr
[Latest Year - Mar2024 - Consolidated Results ] 18.02
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,522.46 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
391% 277% 298% |
SHARE PRICE MOMENTUM OF POLY MEDICURE
POLY MEDICURE vs SENSEX
DEBT OF POLY MEDICURE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.11 0.11 0.1 0.11 |
0.12 0.12 0.12 0.12 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF POLY MEDICURE
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF POLY MEDICURE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
9.16% 10.98% 19.6% 17.8% |
24.52% 36.92% 46.33% 41.32% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
POLY MEDICURE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE 500 | -1.5% | -5.5% | 28.7% |
S&P BSE HEALTHCARE | -1.7% | -2.8% | 50.8% |
S&P BSE MIDSMALLCAP | -1.9% | -5.9% | 39.7% |
S&P BSE 400 MIDSMALLCAP | -2% | -6.6% | 37.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -1.5% | -5.4% | 29.4% |
NIFTY500 MULTICAP 50:25:25 | -1.8% | -5.6% | 31.8% |
NIFTY MID SMALL400 | -1.9% | -6.1% | 36.3% |
NIFTY SMALLCAP250 | -2.8% | -5.6% | 37.2% |
You may also like the below Video Courses
FAQ about POLY MEDICURE
Is POLY MEDICURE good for long term investment?
As on Nov 12,2024, the Fundamentals of POLY MEDICURE look Strong and hence it may be good for long term investment! See Financial Performance of POLY MEDICURE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is POLY MEDICURE UnderValued or OverValued?
As on Nov 12,2024, POLY MEDICURE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of POLY MEDICURE ?
As on Nov 12,2024, the Intrinsic Value of POLY MEDICURE is Rs. 680.85 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 551.69
Fair Value [Median EV / Sales Model] : Rs. 718.20
Fair Value [Median Price / Sales Model] : Rs. 680.85
Estimated Median Fair Value of POLY MEDICURE : Rs. 680.85
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.